Thrombotic thrombocytopenic purpura - A syndrome caused by multiple pathogenetic mechanisms

Investigacion Clinica

Volumn 42, Issue SUPPL. 1, 2001, Pages 75-86

  Lian, E C Y ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Factor von Willebrand; Platelet aggregation; Platelet thrombi; Thrombotic thrombocytopenic purpura

Indexed keywords

CLOPIDOGREL; CORTICOSTEROID; PROSTACYCLIN; TICLOPIDINE; VON WILLEBRAND FACTOR;

APOPTOSIS; BLOOD VESSEL INJURY; CONFERENCE PAPER; CORTICOSTEROID THERAPY; ENDOTHELIUM CELL; ENZYME DEFICIENCY; FIBRINOLYSIS; GENETIC DISORDER; HEMOLYTIC UREMIC SYNDROME; HUMAN; IDIOPATHIC DISEASE; MICROANGIOPATHY; ORGAN TRANSPLANTATION; PATHOGENESIS; PLASMA FACTOR; PLASMAPHERESIS; PROSTAGLANDIN SYNTHESIS; PROTEIN DEGRADATION; SYNDROME; THROMBOCYTE AGGREGATION; THROMBOGENESIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

HUMANS; PLATELET AGGREGATION; PURPURA, THROMBOTIC THROMBOCYTOPENIC; THROMBOSIS;

EID: 0034985362     PISSN: 05355133     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (37)

1. Disseminated arteriolar and capillary platelet thrombus. A morphologic study of its histogenesis
2. Thrombotic thrombocytopenic purpura: Three cases with platelet and fibrinogen survival studies
3. Thrombotic thrombocytopenic purpura: Report of a case with possible immune etiology
4. The vascular pathology of thrombotic thrombocytopenic purpura: An immunohisto-chemical and ultrastructural study
5. Pathologic effect of plasma from patients with thrombotic thrombocytopenic purpura on platelets and cultured endothelial cells
6. Thrombotic thrombocytopenic purpura: Conflicting results of in-vitro studies
7. Minimal evidence of platelet and endothelial cell reactive antibodies in thrombotic thrombocytopenic purpura
8. Plasma from patients with idiopathic and human immunodeficiency virus-associated thrombotic thrombocytopenic purpura induces apoptosis in microvascular endothelial cells
9. Plasma from a patient with thrombotic thrombocytopenic purpura induces endothelial cell apoptosis and platelet aggregation
10. The presence of a platelet aggregating factors in the plasma of patients with thrombotic thrombocytopenic purpura and its inhibition by normal plasma
11. Platelet aggregating activity of plasma in patients with thrombotic thrombocytopenic purpura reviewuated by a particle counting method using light scattering
12. Activated platelet aggregates in thrombotic thromboctyopenic purpura: Decrease with plasma infusions and normalization in remission
13. Inhibition of aggregating activity in thrombotic thrombocytopenic purpura plasma by normal adult immunoglobulin G
14. Platelet aggregation protein p37 from a thrombotic purpura
15. The role of increased platelet aggregation in TTP
16. Purification and some properties of platelet aggregating protein (PAP) from the plasma of a patient with thrombotic thrombocytopenic purpura
17. Thrombotic thrombocytapenic purpura. A review
18. Anti-CD36 antibodies in thrombotic thrombocytopenic purpura
19. Anti-CD36 autoantibodies in thrombotic thrombocytopenic purpura and other thrombotic disorders: Identification of an 85 kD form of CD36 as a target antigen
20. Antibodies to Von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura
21. The pathogenesis of thrombotic thrombocytopenic purpura
22. Fibrinolysis in health and disease: Abnormal levels of plasminogen activator, plasminogen activator inhibitor, and protein C in thrombotic thrombocytopenic purpura
23. In vivo and in vitro effects of thrombin and plasmin on human Factor VIII (AHF)
24. Effects of plasmin on Von Willebrand factor multimers. Degradation in vitro and stimulation of release in vivo
25. Cleavage of human Von Willebrand factor by platelet calcium-activated protease
26. Fibrinogen does not protect von Willebrand factor against proteolysis by human cathepsin G
27. Physiologic cleavage of Von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion
28. Unusually large plasma factor VIII: Von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura
29. Von Willebrand factor abnormalities and endothelial cell perturbation in a patient with acute thrombotic thrombocytopenic purpura
30. Investigation of the role of Von Willebrand factor in thrombotic thrombocytopenic purpura
31. Relationship between platelet aggregating factor and Von Willebrand factor in thrombotic thrombocytopenic purpura
32. Deficiency of Von Willebrand factor-cleaving protease in familial and acquired thrombotic thrombocytopenic purpura
33. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome
34. Von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura
35. Antibody inhibitors to Von Willebrand factor metalloproteinase and increased binding of Von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura
36. Thrombotic thrombocytopenic purpura associated with clopidogrel
37. Von Willebrand factor and thrombotic thrombocytopenic purpura